Eribulin-Pyrotinib Combination Shows Promise in Trastuzumab-Resistant HER2+ Breast Cancer
Key Insights
The EPIC phase II trial demonstrated that eribulin plus pyrotinib achieved a median progression-free survival of 13.47 months in patients with trastuzumab-resistant HER2 (search)-positive advanced breast cancer.
The combination therapy showed a 56.7% objective response rate and 80% disease control rate, with clinical benefit maintained regardless of prior capecitabine treatment.
Safety profile was manageable with predominantly low-grade adverse events, including neutropenia (73.3%) and diarrhea (70%), with only 6.7% of patients discontinuing treatment permanently.
The combination of eribulin mesylate and pyrotinib demonstrated clinically meaningful efficacy and manageable safety in patients with trastuzumab-resistant HER2 (search)-positive advanced breast cancer, according to results from the multicenter phase II EPIC trial published in Drug Design, Development and Therapy.
At a median follow-up of 26 months, the 30 enrolled patients achieved a median progression-free survival (PFS) of 13.47 months (95% CI, 8.17-16.27), with 61.7% of patients remaining progression-free at 12 months. The objective response rate reached 56.7%, including 2 complete responses and 15 partial responses, while the disease control rate was 80.0%.
Study Design and Patient Population
The EPIC trial enrolled female patients aged 18-70 years with histologically confirmed HER2 (search)-positive advanced breast cancer who had documented disease progression following prior taxane chemotherapy and trastuzumab-based therapy. HER2 positivity was defined as immunohistochemistry 3+ and/or fluorescence in situ hybridization ratio of at least 2.0.
Patients received oral pyrotinib at 400 mg once daily combined with intravenous eribulin at 1.4 mg/m² on days 1 and 8 of each 28-day cycle for six consecutive cycles, followed by pyrotinib monotherapy until disease progression or unacceptable toxicity.
The median age of enrolled patients was 57 years, with 86.7% having visceral metastatic sites and 70% having estrogen or progesterone receptor-positive disease. Most patients (80%) had received two prior lines of therapy, and 53.3% had received trastuzumab for advanced disease treatment.
Efficacy Outcomes
The combination demonstrated notable durability of response, with a median duration of response of 23.03 months (95% CI 21.7-NR) and maximum duration exceeding 34 months. The clinical benefit rate, defined as complete response, partial response, or stable disease maintained for at least 6 months, reached 73.3%.
Survival data showed promise, with a 12-month overall survival rate of 75.3% (95% CI, 66.2%-84.4%), though median overall survival was not reached at the data cutoff. Importantly, prespecified subgroup analysis revealed consistent treatment effects regardless of prior capecitabine therapy (HR 1.02, 95% CI 0.42-2.48; P = 0.5641).
Safety Profile
The safety profile aligned with known toxicity patterns of both agents. Treatment-emergent adverse events occurred in 90% of patients, with grade 3 or higher events in 33.3%. The most common adverse events were neutropenia (73.3%), diarrhea (70%), nausea/vomiting (66.7%), and peripheral neuropathy (63.3%).
Grade 3 or 4 adverse events included neutropenia (16.7%), elevated liver enzymes (13.3%), peripheral neuropathy (10%), nausea/vomiting (6.7%), anemia (3.3%), and diarrhea (3.3%). Dose modifications were required in 23.3% of patients, while 6.7% permanently discontinued treatment. No treatment-related deaths occurred.
Clinical Context and Implications
"To our knowledge, this represents the first multicenter phase II trial investigating pyrotinib combined with eribulin in HER2 (search)-positive advanced breast cancer patients exhibiting primary trastuzumab resistance," wrote lead author Ruoyang Li, MD, of the Breast Center at the Fourth Hospital of Hebei Medical University (search), and colleagues.
The results compare favorably with established second-line treatments. The EMILIA trial showed trastuzumab emtansine achieved a median PFS of 9.6 months versus 6.4 months for lapatinib/capecitabine. The DESTINY-Breast03 trial demonstrated trastuzumab deruxtecan's superiority with a median PFS of 28.8 months versus 6.8 months for trastuzumab emtansine.
The combination's mechanism involves eribulin's unique microtubule-targeting effects, which differ from taxanes by suppressing microtubule growth without affecting shortening phases, potentially circumventing classical taxane resistance pathways. Pyrotinib, a second-generation irreversible pan-HER tyrosine kinase inhibitor targeting EGFR (search), HER2 (search), and HER4 (search), provides complementary anti-HER2 activity.
Study Limitations and Future Directions
The researchers acknowledged several limitations, including the single-arm design with potential selection bias, modest sample size of 30 patients, and exclusive enrollment of Chinese patients, which may limit generalizability. The study also relied on investigator-assessed endpoints without independent radiological review.
"The combination regimen of eribulin and pyrotinib demonstrated a safe and feasible option for second-line treatment in patients with HER2 (search)-positive advanced breast cancer," the authors concluded. "However, the current evidence is limited to Phase II clinical trial data, necessitating further validation through expanded sample sizes and controlled studies."
The findings were presented at the 2025 ASCO Annual Meeting, highlighting the potential of this combination as a new therapeutic option for patients with trastuzumab-resistant HER2 (search)-positive breast cancer, a population with significant unmet medical needs.